Curative Study of Chinese Traditional Medicine to Treat Lung Cancer

NCT ID: NCT02777788

Last Updated: 2017-10-10

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2019-12-31

Brief Summary

The purpose of this study is to observe the efficacy of chemotherapy combined with Chinese patent drugs for patients with advanced non-small-cell lung cancer, also to evaluate the adverse reaction and the reliability.

Detailed Description

Lung cancer is the most common malignant tumor in the world with about 80%-85% non small cell lung cancer.

The investigators perform a multi-center, randomized, controlled, prospective study in patients with advanced NSCLC. Patients are randomized over observational group(Chinese patent drugs plus chemotherapy), and control group (chemotherapy). The investigators will observe 2 cycles and after that regular follow-up will be arranged.

The primary end point is: Objective response rate;

The secondary end points are:

1. progression-free survival(PFS);

2. overall survival(OS);

3. Time to Progression (TTP);

4. quality of life questionnaire（QOL);

5. other end points are: Toxicity, side effects and security of the treatments will be assessed at the same time.

The investigators expect that integrated TCM combined with chemotherapy has a better efficacy on enhancing Objective response rate，prolonging PFS, OS, improving QOL, reducing the adverse reaction of patients than that of chemotherapy.Therefore our study can provide evidences for optimizing and promoting integrated TCM combined with Western Medicine treatment.

Conditions

Cancer

Keywords

Chinese Traditional Medicine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

chemotherapy

Eligible subjects will be treated with platinum-doublet 2 cycles chemotherapy:pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin. Each cycle was 21-days.

Dosage:pemetrexed i.v.500mg/m2 d1 ; docetaxel i.v.75mg/m2 d1 ; gemcitabine i.v.1250 mg/m2 d1,d8 ; paclitaxel i.v.175mg/m2 d1 ; vinorelbine i.v.25mg/m2 d1,d8; carboplatin i.v.area under curve (AUC) 5 d1 ；cis-platinum i.v.75mg/m2 d1（or divided into 3days）；nedaplatin i.v.80mg/m2 d1.

Group Type: ACTIVE_COMPARATOR

pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin

Intervention Type: DRUG

TCM combined chemotherapy

TCM：JinFuKang plus XingZaoRuanJian, chemotherapy will be the same. JinFuKang po.tid.30ml d6-d21 XingZaoRuanJian po.tid.30ml d6-d21

Group Type: EXPERIMENTAL

JinFuKang

Intervention Type: DRUG

treated with chemotherapy

XingZaoRuanJian

Intervention Type: DRUG

treated with chemotherapy

Interventions

JinFuKang

treated with chemotherapy

Intervention Type: DRUG

XingZaoRuanJian

treated with chemotherapy

Intervention Type: DRUG

pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin

Intervention Type: DRUG

Other Intervention Names

JinFuKang oral liquid; RuanHuaTang

Eligibility Criteria

Inclusion Criteria

1. Pathologically or cytologically confirmed of stage Ⅲb-Ⅳ NSCLC

2. Ages Eligible for Study: 18-65 years old;

3. Physical status score (ECOG PS) ≤ 2 scores；

4. Estimated life expectancy of at least 6 months；

5. Participants have no major organ dysfunction and chemotherapy contraindications: hemoglobin ≥10g/dL, absolute neutrophil count (ANC) ≥1.5*109/L, platelets ≥80*109/L, Liver and kidney function is normal;

6. Informed consent from the patient.

Exclusion Criteria

1. Patient with other malignant tumor except NSCLC 5 years previous to study entry.

2. Patients who have received targeted drug treatment；

3. Serious problem of heart, liver or kidney with severe dysfunction;

4. Pregnant or child breast feeding women;

5. Mental or cognitive disorders;

6. Participating in other drug trials;

7. Who are allergic to the study drug.

8. Diabetic patients.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Chest Hospital

OTHER

Sponsor Role: collaborator

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

Sponsor Role: collaborator

Shanghai University of Traditional Chinese Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

HEGEN LI

Role: STUDY_DIRECTOR

Shanghai University of Traditional Chinese Medicine

Other Identifiers

ZY3-CCCX-3-3023

Identifier Type: -

Identifier Source: org_study_id